Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study

被引：0
|
作者：
Gruenig, Ekkehard [1 ]
Galie, Nazzareno [2 ]
Humbert, Marc [3 ,4 ,5 ]
Keogh, Anne M. [6 ]
Langleben, David [7 ]
Rubin, Lewis J. [8 ]
Speich, Rudolf [9 ]
Fritsch, Arno [10 ]
Davie, Neil [10 ]
Ghofrani, Hossein-Ardeschir [11 ,12 ]
机构：
[1] Univ Heidelberg Hosp, Thoraxclin, Thoraxclin Heidelberg, Ctr Pulm Hypertens, Heidelberg, Germany
[2] Univ Bologna, Inst Cardiol, Bologna, Italy
[3] Univ Paris 11, Le Kremlin Bicetre, France
[4] INSERM, F-94275 Le Kremlin Bicetre, France
[5] Hop Bicetre, AP HP, Serv Pneumol, Le Kremlin Bicetre, France
[6] St Vincents Hosp, Heart Lung Transplant Unit, Sydney, NSW 2010, Australia
[7] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Pulm Vasc Dis, Montreal, PQ H3T 1E2, Canada
[8] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[9] Univ Zurich Hosp, Dept Internal Med, Zurich, Switzerland
[10] Bayer HealthCare Pharmaceut, Global Clin Dev, Wuppertal, Germany
[11] Univ Giessen, Dept Internal Med, Giessen, Germany
[12] Marburg Lung Ctr UGMLC, Giessen, Germany
来源：
EUROPEAN RESPIRATORY JOURNAL | 2013年 / 42卷
关键词：
Pulmonary hypertension; Treatments; Nitric oxide;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
2347
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Riociguat in Pulmonary Arterial Hypertension (PAH): Evaluation of Abbreviated Versions of the ESC/ERS Risk Assessment Tool in PATENT-2
    Humbert, M.
    Farber, H. W.
    Ghofrani, H.
    Busse, D.
    Meier, C.
    Hoeper, M. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [32] Effectiveness and Safety of Riociguat as First-line or Combination Therapy in Pulmonary Arterial Hypertension (PAH): A Riociguat Users (ROAR) Registry Analysis
    White, R.
    Aranda, A. U.
    Chakinala, M. M.
    Mandras, S.
    Mcconnell, J. W.
    Miller, C. E.
    Sulica, R.
    Johnson, D.
    Carvajal, V.
    Bansilal, S.
    Kirkwold, J.
    Kim, N. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [33] Effects of riociguat in treatment-naive versus pretreated patients with pulmonary arterial hypertension (PAH): 1-year results from the PATENT-2 long-term extension (LTE) study
    Jansa, P.
    Galie, N.
    Ghofrani, H. A.
    Humbert, M.
    Keogh, A. M.
    Langleben, D.
    Rubin, L. J.
    Vizza, D.
    Wang, C.
    Hoeper, M.
    EUROPEAN HEART JOURNAL, 2014, 35 : 10 - 10
  • [34] Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial
    Frantz, R. P.
    McLaughlin, V. V.
    Sahay, S.
    Subias, P. Escribano
    Zolty, R. L.
    Benza, R. L.
    Channick, R. N.
    Chin, K. M.
    Hemnes, A. R.
    Howard, L. S.
    Sitbon, O.
    Vachiery, J.
    Zamanian, R. T.
    Cravets, M.
    Roscigno, R. F.
    Mottola, D.
    Elman, E.
    Parsley, E.
    Aranda, R.
    Zisman, L. S.
    Ghofrani, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [35] Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study
    Halank, Michael
    Hoeper, Marius M.
    Ghofrani, Hossein-Ardeschir
    Meyer, F. Joachim
    Staehler, Gerd
    Behr, Juergen
    Ewert, Ralf
    Fletcher, Monique
    Colorado, Pablo
    Nikkho, Sylvia
    Grimminger, Friedrich
    RESPIRATORY MEDICINE, 2017, 128 : 50 - 56
  • [36] Riociguat for the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Update from the EXPERT Registry
    Klose, H.
    Gall, H.
    Ghofrani, H.
    Gruenig, E.
    Humbert, M.
    Simonneau, G.
    Halank, M.
    Langleben, D.
    Snijder, R. J.
    Escribano, P.
    Mielniczuk, L. M.
    Lange, T.
    Vachiery, J.
    Wirtz, H.
    Helmersen, D. S.
    Tsangaris, I.
    Barbera, J. A.
    Pepke-Zaba, J.
    Boonstra, A.
    Rosenkranz, S.
    Ulrich, S.
    Mascherbauer, R.
    Delcroix, M.
    Jansa, P.
    Gomez Sanchez, M. A.
    Klotsche, J.
    Meier, C.
    Pittrow, D.
    Hoeper, M. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [37] Characterization Of Chinese Patients With Pulmonary Arterial Hypertension Or Chronic Thromboembolic Pulmonary Hypertension: Baseline Characteristics From The Patent-1 And Chest-1 Studies And Comparison With Other Studies
    He, J.
    Wang, C.
    Jing, Z. -C.
    Huang, Y.
    Zhou, D.
    Liu, Z. -H.
    Meier, C.
    Nikkho, S.
    Curram, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [38] Measuring Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Not on Active Treatment (MOTION): A Study of the Effects of Riociguat on Patient-Reported Outcomes and an Exploration of Telemetric Technology in PAH
    Mathai, Stephen
    Minai, Omar
    Sullivan, Sean
    Lerner, Debra
    Levine, Deborah
    Platt, David
    O'Brien, Gerald
    Satler, Carol
    CHEST, 2015, 148 (04)
  • [39] Riociguat For Chronic Thromboembolic Pulmonary Hypertension And Pulmonary Arterial Hypertension: First Long-term Extension Data From A Phase II Study
    Ghofrani, H.
    Hoeper, M. M.
    Halank, M.
    Meyer, F. J.
    Staehler, G.
    Behr, J.
    Ewert, R.
    Binnen, T.
    Weimann, G.
    Grimminger, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [40] A Phase 2 Study of the Soluble Guanylate Cyclase Stimulator Riociguat in Patients with Chronic Thromboembolic Pulmonary Hypertension or Pulmonary Arterial Hypertension
    Ghofrani, Hossein-Ardeschir
    Hoeper, Marius M.
    Halank, Michael
    Meyer, F. Joachim
    Staehler, Gerd
    Behr, Juergen
    Ewert, Ralf
    Weimann, Gerrit
    Grimminger, Friedrich
    CIRCULATION, 2010, 122 (02) : E239 - E239
12345